Health groups warn DTC drug ad bans could harm patients and competition

A group of organisations has spoken out against proposals to ban or over-regulate direct-to-consumer (DTC) advertising for prescription drugs. They argue that such restrictions would harm patients by reducing access to medical information and limiting treatment choices.

The coalition warns that stricter rules would also stifle competition, particularly for smaller and newer companies that depend on these ads to reach patients. Research shows that DTC ads play a significant role in patient behaviour. A study found that 33% of adults search for health information after seeing a TV ad about symptoms. Another report revealed that 55% of consumers have asked their doctor for a specific drug after viewing an advertisement.

These ads also encourage more doctor visits and improve medication adherence, according to findings from multiple universities. The organisations highlight that 15% of DTC spending goes toward unbranded disease awareness campaigns, which educate the public without promoting specific products.

The coalition stresses that banning or heavily restricting DTC ads would leave patients less informed about available treatments. They argue that fewer advertisements would reduce market competition, leading to higher drug prices and fewer options for those in need. The organisations are urging lawmakers to protect patients' right to access medical information through DTC advertising. They claim that without these ads, many people would remain unaware of critical treatment options. The group also warns that smaller companies, which rely on such advertising, would struggle to compete in an already concentrated market.